Abstract: The present invention relates to the use of compositions for monitoring, diagnosis, detecting, and treating a cancer condition in a subject. The use of composition comprises methods of monitoring, diagnosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.

Abstract: The present invention relates to the use of compositions for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit TCF/LEF activity. The pharmaceutical composition will further comprise agents that inhibit TCF/LEF activity in a subject.

Abstract: The present invention relates to the use of compositions for monitoring, diagnosis, detecting, and treating a cancer condition in a subject. The use of composition comprises methods of monitoring, diagnosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.

Abstract: The present invention relates to the use of compositions and methods for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit Hedgehog pathway activity. The pharmaceutical composition will further comprise agents that inhibit Smoothened receptor and/or Gli transcription in a subject.

Abstract: The present invention relates to the use of compositions for treating or preventing a condition in a subject by inhibiting androgen signaling. The use of composition comprises methods of treating or preventing cancer with agents that inhibit androgen signaling. The pharmaceutical composition will further comprise agents that inhibit Androgen receptor activity, transcription, or expression in a subject.

Abstract: The present invention relates to the use of compositions and methods for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit Hedgehog pathway activity. The pharmaceutical composition will further comprise agents that inhibit Smoothened receptor and/or Gli transcription in a subject.

Abstract: The present invention relates to the use of compositions for treating or preventing a cancer condition in a subject. The use of composition comprises methods of treating or preventing cancer with agents that inhibit Nanog expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit Nanog expression or activity in a subject.

Abstract: The present invention relates to the field of cancer and inflammation, and in particular methods of monitoring, diagnosis, prognosis, detecting, treating and preventing cancer and inflammation conditions. The use of composition comprises method of monitoring, diagnosis, prognosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.

Abstract: This invention is directed to compositions and methods for treating cancer in a patient.

Abstract: This invention is directed to compositions, methods and kits that can be used for reducing cell viability, inducing cell apoptosis, and inhibiting cell proliferation, such as for the treatment of cancer. The invention is also directed to compositions, methods and kits that can be used for treating inflammatory conditions, such as by modulating inflammatory cytokines.

Abstract: This invention is directed to compositions and methods for treating cancer in a patient.

Abstract: This invention is directed to methods for treating cancer and metabolic syndrome.

Abstract: This invention is directed to compositions, methods and kits that can be used for reducing cell viability, inducing cell apoptosis, and inhibiting cell proliferation, such as for the treatment of cancer. The invention is also directed to compositions, methods and kits that can be used for treating inflammatory conditions, such as by modulating inflammatory cytokines.

Abstract: The invention relates to compositions and methods for treating cancer comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, methods of inhibiting the growth of cancer stem cells or tumor initiating cell comprising administering to a subject in need a pharmaceutically effective dose of a cancer stem cell inhibitor, and methods of enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells comprising administering to a subject in need a pharmaceutically effective dose of a chemotherapeutic drug and a pharmaceutically effective dose of a cancer stem cell inhibitor.

Abstract: This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.